LKFT (Lakefront Biotherapeutics NV) Cyclically Adjusted PS Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LKFT Lakefront Biotherapeutics NV LKFT
58 GF Score
Price $28.55
GF Value $114.79
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Lakefront Biotherapeutics NV Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Lakefront Biotherapeutics NV  (NAS:LKFT) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Lakefront Biotherapeutics NV Cyclically Adjusted PS Ratio Related Terms


Lakefront Biotherapeutics NV Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Lakefront Biotherapeutics NV's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lakefront Biotherapeutics NV Cyclically Adjusted PS Ratio Chart

Lakefront Biotherapeutics NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.47 6.61 6.03 3.93 3.68

Lakefront Biotherapeutics NV Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.96 4.54 3.52 3.20 3.17

LKFT vs VRTX, REGN, MRNA: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Lakefront Biotherapeutics NV's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lakefront Biotherapeutics NV Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lakefront Biotherapeutics NV's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Lakefront Biotherapeutics NV's Cyclically Adjusted PS Ratio falls into.


LKFT
58GF Score
Lakefront Biotherapeutics NV LKFT
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lakefront Biotherapeutics NV Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Lakefront Biotherapeutics NV's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Lakefront Biotherapeutics NV's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.201/138.0500*138.0500
=0.201

Current CPI (Jun. 2026) = 138.0500.

Lakefront Biotherapeutics NV Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.698 102.267 0.942
201609 0.272 102.118 0.368
201612 1.810 102.614 2.435
201703 0.753 103.972 1.000
201706 0.625 103.902 0.830
201709 0.626 104.170 0.830
201712 0.907 104.804 1.195
201803 0.914 105.419 1.197
201806 1.153 106.063 1.501
201809 2.032 106.618 2.631
201812 2.191 107.252 2.820
201903 0.687 107.876 0.879
201906 1.204 107.896 1.540
201909 11.766 107.470 15.114
201912 2.042 108.065 2.609
202003 1.615 108.550 2.054
202006 1.681 108.540 2.138
202009 2.280 108.441 2.903
202012 2.633 108.511 3.350
202103 2.097 109.522 2.643
202106 2.570 110.305 3.216
202109 1.155 111.543 1.429
202112 2.912 114.705 3.505
202203 2.330 118.620 2.712
202206 2.231 120.948 2.546
202209 2.084 124.120 2.318
202212 1.473 126.578 1.607
202303 0.954 126.528 1.041
202306 0.992 125.973 1.087
202309 1.010 127.083 1.097
202403 1.028 130.552 1.087
202406 1.272 130.691 1.344
202409 0.998 130.968 1.052
202412 1.222 132.346 1.275
202503 1.197 134.348 1.230
202506 1.123 133.495 1.161
202509 1.262 133.740 1.303
202512 15.911 135.080 16.261
202603 0.115 136.570 0.116
202606 0.201 138.050 0.201

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Lakefront Biotherapeutics NV (LKFT) Overvalued in 2026?

Based on GuruFocus' analysis, Lakefront Biotherapeutics NV stock appears to be undervalued. The current stock price of $28.55 is trading 75.1% below its estimated GF Value™ of $114.79. GuruFocus considers Lakefront Biotherapeutics NV to be Possible Value Trap.

Key valuation signals for LKFT:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: $114.79 vs. price of $28.55 (75.1% below fair value)
  • GF Score™: 58/100 with 4 warning signs

No single metric tells the full story. See the LKFT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lakefront Biotherapeutics NV Business Description

Address Schalienhoevedreef 20 T, Mechelen, BEL, 2800
Lakefront Biotherapeutics NV a biopharmaceutical company committed to improving the lives of people with severe diseases. It focuses on delivering medicines with transformational impact for patients by accelerating life-changing science and innovation in areas of high unmet need. Its pipelines includes GLPG3667, GLPG5101, and GLPG5301.
58GF Score

Get the complete analysis for LKFT

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$28.55
Price
$114.79
GF Value